Search results for "Metabolic"

showing 10 items of 2205 documents

HLA class II haplotypes differentiate between the adult autoimmune polyglandular syndrome types II and III.

2013

Background: Genetics of the adult autoimmune polyglandular syndrome (APS) is poorly understood. Aim: The aim of this study was to gain further insight into the genetics of the adult APS types. Site: The study was conducted at a university referral center. Methods: The human leukocyte antigen (HLA) class II alleles, haplotypes, and genotypes were determined in a large cohort of patients with APS, autoimmune thyroid disease (AITD), and type 1 diabetes and in healthy controls by the consistent application of high-resolution typing at a four-digit level. Results: Comparison of the allele and haplotype frequencies significantly discriminated patients with APS vs AITD and controls. The HLA class…

musculoskeletal diseasesHla class iiAdultMaleendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismClinical BiochemistryGenes MHC Class IIHuman leukocyte antigenBiochemistryDiagnosis DifferentialYoung AdultEndocrinologyGene FrequencyAutoimmune Polyglandular SyndromeGenotypeMedicineHumansGenetic Predisposition to DiseaseTypingAlleleskin and connective tissue diseasesChildPolyendocrinopathies AutoimmuneType 1 diabetesbusiness.industryBiochemistry (medical)Haplotypenutritional and metabolic diseasesMiddle Agedmedicine.diseaseHaplotypesCase-Control StudiesImmunologyFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous oxidative DNA b…

2002

The Cockayne syndrome B (CSB) gene product is involved in the repair of various types of base modifications in actively transcribed DNA sequences. To investigate its significance for the repair of endogenous oxidative DNA damage, homozygous csb(-/-)/ogg1(-/-) double knockout mice were generated. These combine the deficiency of CSB with that of OGG1, a gene coding for the mammalian repair glycosylase that initiates the base excision repair of 7,8-dihydro-8-oxoguanine (8-oxoG). Compared to ogg1(-/-) mice, csb(-/-)/ogg1(-/-) mice were found to accumulate with age severalfold higher levels of oxidited purine modifications in hepatocytes, splenocytes and kidney cells. In contrast, the basal (ste…

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchDNA RepairTranscription GeneticDNA damageDNA repairBiologyGene productMicechemistry.chemical_compoundGeneticsAnimalsPoly-ADP-Ribose Binding ProteinsMolecular BiologyGeneDNA PrimersMice KnockoutBase SequenceHomozygoteDNA HelicasesDeoxyguanosinenutritional and metabolic diseasesBase excision repairMolecular biologyOxidative StressDNA Repair EnzymesBiochemistrychemistry8-Hydroxy-2'-DeoxyguanosineDNA glycosylaseDNADNA DamageNucleotide excision repairOncogene
researchProduct

Granuloma anulare disseminatum als seltene Nebenwirkung von Allopurinol

1995

During long-term therapy of hyperuricaemia with allopurinol (300 mg/d) two patients developed generalized granuloma annulare. The diagnoses were confirmed by histology; concomitant diseases, especially diabetes mellitus, were not detectable. Following discontinuation of allopurinol therapy, cutaneous granulomas healed without relapse. Hyperuricaemia could be controlled by low-purine diet and medication avoiding allopurinol. The clinical history of our two patients suggested a causal connection between allopurinol therapy and generalized granuloma annulare. For this reason we rate the development of this disease in both cases as a rare but significant side effect of allopurinol. This should …

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyChemotherapySide effectbusiness.industrymedicine.medical_treatmentnutritional and metabolic diseasesAllopurinolDermatologymedicine.diseaseConcomitant drugDermatologyDiscontinuationGranulomaConcomitantmedicinebusinessmedicine.drugGeneralized granuloma annulareDer Hautarzt
researchProduct

Mucopolysaccharidoses and other lysosomal storage diseases.

2013

Mucopolysaccharidosis and other lysosomal storage diseases are rare, chronic, and progressive inherited diseases caused by a deficit of lysosomal enzymes. Patients are affected by a wide variety of symptoms. For some lysosomal storage diseases, effective treatments to arrest disease progression, or slow the pathologic process, and increase patient life expectancy are available or being developed. Timely diagnosis is crucial. Rheumatologists, orthopedics, and neurologists are commonly consulted due to unspecific musculoskeletal signs and symptoms. Pain, stiffness, contractures of joints in absence of clinical signs of inflammation, bone pain or abnormalities, osteopenia, osteonecrosis, secon…

musculoskeletal diseasesmedicine.medical_specialtyPathologyMucopolysaccharidosisPainOsteochondrodysplasiasHip dysplasia (canine)RheumatologyInternal medicineLysosomal storage diseasemedicineHumansMusculoskeletal DiseasesBone painHip Dislocation CongenitalMuscle contractureHip Contracturebusiness.industryOsteonecrosisMucopolysaccharidosesPrognosismedicine.diseaseOsteopeniaBone Diseases MetabolicEarly DiagnosisHip ContractureOrthopedic surgeryHip JointJointsJoint Diseasesmedicine.symptomLysosomesbusiness
researchProduct

Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis

2009

Abstract Background Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (l…

musculoskeletal diseasesmedicine.medical_specialtyPediatricscongenital hereditary and neonatal diseases and abnormalitieslcsh:Diseases of the musculoskeletal systemIdursulfaseMucopolysaccharidosisDiseaseRheumatologyInternal medicinemedicineImmunology and AllergyPediatrics Perinatology and Child HealthYoung adultCarpal tunnel syndromeskin and connective tissue diseasesbusiness.industrylcsh:RJ1-570nutritional and metabolic diseaseslcsh:PediatricsEnzyme replacement therapyHypothesismedicine.diseaseRheumatologyJoint painPediatrics Perinatology and Child Healthmedicine.symptomlcsh:RC925-935businessmedicine.drugPediatric Rheumatology
researchProduct

Myoadenylate deaminase deficiency

1987

Myoadenylate deaminase (MAD) is the rate-limiting enzyme in the purine nucleotide cycle which is biochemically linked to glycolysis and the citric cycle and thereby providing energy during intense muscular activity. In muscle fibers, myoadenylate deaminase operates at considerably higher activity levels than in other organs. First detected using enzyme-histochemical methods, it now appears that deficiency of myoadenylate deaminase is one of the most frequent enzyme defects in muscle. The primary defect may occur as an isolated nosological entity or not infrequently it is also associated with a large spectrum of different neuromuscular conditions. It seems to be the primary unassociated MAD …

myalgiaWeaknessmedicine.medical_specialtyBiopsyElectromyographyMetabolic myopathyBiologyGastroenterologyAMP Deaminase03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryBiopsymedicineHumansGenetics (clinical)030304 developmental biology0303 health sciencesmedicine.diagnostic_testMusclesMuscle weaknessAMP deaminaseNeuromuscular DiseasesGeneral Medicinemedicine.diseaseEndocrinologyNucleotide DeaminasesMolecular MedicineSarcoidosismedicine.symptom030217 neurology & neurosurgeryKlinische Wochenschrift
researchProduct

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

Serum metabolic profiles in overweight and obese women with and without metabolic syndrome.

2014

Objective: To identify serum biomarkers through metabolomics approach that distinguishes physically inactive overweight/obese women with metabolic syndrome from those who are metabolically healthy, independent of body weight and fat mass. Methods: We applied nuclear magnetic resonance spectroscopy-based profiling of fasting serum samples to examine the metabolic differences between 78 previously physically inactive, body weight and fat mass matched overweight/obese premenopausal women with and without MetS. MetS was defined as the presence of at least three of the following five criteria: waist circumference ≥ 88 cm, serum triacylglycerol ≥ 1.7 mmol/L, and high density lipoprotein cholester…

naisetbusiness.industryEndocrinology Diabetes and MetabolismResearchMEDLINEOverweightmedicine.diseaseBioinformaticsBody weightmetabolomicsObesityMetabolic syndromeFat massMetabolomicsDiabetes mellitusmedicineInternal MedicinelihavuusMetabolomicsWomenObesityMetabolic syndromemedicine.symptombusinessmetabolinen oireyhtymäDiabetologymetabolic syndrome
researchProduct

Shorter recovery time following high-intensity interval training induced higher body fat loss among overweight women

2018

Background: High intensity interval training (HIIT) has been widely employed as an exercise protocol to reduce fat, and also in addition, interval recovery periods are the most important factors which can have great impact on weight loss. Therefore, the aim of this study was the evaluation of different recovery time between HIIT program on metabolic responses and weight loss in overweight women. Methods: Twenty-four overweight (BMI 29.5±3.5 kg/m2) volunteer women were randomly assigned into three groups (n=8/group) to study the effects of different recovery times: (group 1; HIIT with 60/60 activity-rest ratio (sec), group 2; HIIT with 60/30 activity-rest ratio (sec), and group 3 was set as …

naisetmedicine.medical_specialtyoverweight womenSports medicinepalautuminenHIITPhysiology030204 cardiovascular system & hematologyOverweightBody fat percentageInterval training03 medical and health sciences0302 clinical medicineInsulin resistancemetabolic indicesWeight lossmedicineOrthopedics and Sports MedicineaineenvaihduntaVolunteerbusiness.industrylaihdutusylipaino030229 sport sciencesintervalliharjoittelumedicine.diseaseinterval recovery timemedicine.symptombusinessHigh-intensity interval trainingSport Sciences for Health
researchProduct

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease

2021

Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32)

nonalcoholic fatty liver disease0301 basic medicinemedicine.medical_specialtyBetatrophinEndocrinology Diabetes and Metabolismmedicine.medical_treatmentbetatrophin030209 endocrinology & metabolismMicrobiologydigestive systemBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceinsulin resistanceInternal medicineNonalcoholic fatty liver diseaseMedicineMolecular BiologyBetatrophin Glucose intolerance Insulin resistance Nonalcoholic fatty liver diseaseTriglyceridebusiness.industryInsulinnutritional and metabolic diseasesLipid metabolismmedicine.diseaseQR1-502digestive system diseases030104 developmental biologyEndocrinologyglucose intolerancechemistrySteatosisbusinessHormoneMetabolites
researchProduct